I don’t see ”Vascular Tissue” adding much value to share price. My reasoning is simple. I think that the vascular tissue cost center operating margin is so low, that after subtracting off the related operating expenses that the cost center has an operating loss. I don’t expect this to change either, because if it were possible CRY would have done it long ago. CRY has never, to my knowledge/recollection, ever said this cost center is currently profitable. CRY has had plenty of opportunity to comment on profitability at this cost center, but so far they have been silent.
Check these revenue numbers yourself, since you are responsible for doing your own due diligence.
Dirty lab and a possible liability tail to boot? Not likely, but the probability is not zero either. So why take the risk when this cost center is just a gerbil wheel factory?
Conclusion: Amigo, draw your own conclusions. You are responsible for your own due diligence.